Articles On Paradigm Biopharmaceuticals (ASX:PAR)

World Overnight SPI Overnight (Jun) 7460.00 + 17.00 0.23% S&P ASX 200 7504.50 + 16.20 0.22% S&P500 4528.79 + 19.42 0.43% Nasdaq Comp 15265.89 + 136.39 0.90% DJIA 35399.84 – 55.96 – 0.16% S&P500 VIX 16.19 – 0.20 – 1...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AFG)) - Australian Finance Group ((BGA)) - Bega Cheese ((BEX)) - BikeExchange ((DTC)) - Damstra holdings ((DDH)) - DDH1 ((GDG)) - Generation Development ((GNX)) - Genex...

“The achievements of FY21 are important in our journey as a company and help set a strong foundation for Paradigm to grow,” says interim chair and CEO.

Highlights The ASX 200 was down 3.7 points to 7,487.5 during opening trade. The market breadth is reflecting investors’ mood of booking profits on the back of global cues as 7 out of the 11 sectors are trading lower. BWX’s EBITDA for...

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Zilosul® was made available during the second quarter to physicians with SAS approval to treat patients experiencing chronic arthralgia from Ross River virus (RRV) infection.

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a decline. At the time of writing, the benchmark index is down 0.35% to 7,466.6 points. Four ASX shares that are falling more than most today are listed...

Pentosan polysulfate sodium (PPS) is currently being evaluated by Paradigm for potential registration for the treatment of osteoarthritis and other inflammatory diseases in the US and other major global markets.

ASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by 0.19%. A class action proceeding against Mayne Pharma (ASX:MYX) has been brought by Phi Finney McDonald on behalf on investors who bought MY...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is under significant pressure on Tuesday morning. At the time of writing, the biopharmaceutical company’s shares are down 14.5% to $1.90. This decline means the Paradigm share pric...

Local markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday as some major M&A activity stole the headlines. Gains were led by the tech sector, as Afterpay (ASX:APT) showed its weight by dragging th...

The armed forces could be called upon to enforce Sydney’s strict lockdown, and we might see troops on the streets as early as Monday. On the bourse, the benchmark ASX 200 has closed 0.40% lower on Friday, but was flat for the week. The mini...

Securities will remain halted until Tuesday, August 3, 2021, or when an announcement is released to the market.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.6% to 7,346.2 points. Four ASX shares that are climbing more than most are listed below. Her...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is edging higher during early morning trade. This comes after the company provided an update on its Investigational New Drug (IND) application to the US Food and Drug Administratio...

The late-stage drug development company has a mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders.

NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM. The company has found a research partner in Perth-based Linear Clinical Research. Linear operates a clinical trials facility on...

After overseeing Paradigm Biopharmaceuticals’ (ASX:PAR) rise to 14-bagger highs, Paul Rennie has joined NeuroScientific Biopharmaceuticals (ASX:NSB) as Non-executive Chairman. The appointment is a substantial win for NeuroScientific given R...

Summary The ASX 200 rebounded strongly from opening losses and reclaimed 7,400 levels. The market rally was driven by strong gains in technology, telecom, and healthcare stocks. BNPL player ZIP Co was the top performer on the ASX with...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is running higher today after the company announced key clinical trial approvals in Brazil. The Paradigm share price is currently up 5.5%, trading at $2.10. Paradigm is currently...

This will be the largest clinical trial conducted using PPS in any MPS type subjects, and will evaluate the safety and tolerability of the drug as well as its effects on mobility, urinary GAG levels, walking-related pain, quality of life an...

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.7% to 7,095.9 points. Four ASX shares that have failed to follow the market higher today are...

The company is on track to respond to questions from the US Food and Drug Administration around its Investigational New Drug application within 30 days.

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco...

Summary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of the 11 sectors traded in the green, while tech stocks lead the pack with a 4.32% gain.  Afterpay emerges as the top gainer, followed by Redbu...

Summary The ASX 200 is heading towards its worst performance since late February, down 2% at 6924.10 at the close. The market breadth was extremely week, with all the 11 sectoral indices trading in red. EML Payments shares plunged ove...

Under the pay-for-use SAS program, Paradigm has already received five prescriptions for Zilosul® from physicians and the five patients will commence Zilosul® treatment in the coming week.

Summary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead programs in the US and Japan, respectively. Paradigm Biopharmaceuticals has received first revenue through a physician prescription of Zilosul®....

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 1.8% to 6,937.6 points. Four ASX shares that haven’t let that hold them back...

Summary The Australian shares opened lower on Wednesday after rising in the last three sessions. The domestic equity benchmark ASX 200 opened lower by 17.60 points or 0.25% to 7,048.40. The benchmark traded in the negative zon...

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,057.7 points. Four ASX shares that are falling more t...

The share price of Paradigm Biopharmaceuticals Ltd (ASX: PAR) is down today on an update of its new drug application. What does this mean for the Paradigm share price? Paradigm has repurposed an anti-inflammatory drug called pentosan polysu...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has started the week in the red. In morning trade, the clinical stage biopharmaceutical company’s shares are down just under 5% to $2.44. Why is the Paradigm share price sinking lo...

The FDA was unable to provide all questions within the initial IND review period and has advised it will submit further questions to Paradigm within the next 30 days.

The study will investigate changes in knee synovial fluid biomarkers associated with pain, inflammation and disease progression of knee Osteoarthritis.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a positive performer on Wednesday. In morning trade, the biopharmaceutical company’s shares are up 3% to $2.65. Why is the Paradigm share price charging higher? Investors...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Source:Ratanapon Srisuneton, Shutterstock Summary Opthea gets an iPSP waiver from the FDA for its lead product candidate to treat wet AMD. Paradigm and bene pharmaChem set to collaborate for the development of iPPS and other formulati...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the rise this morning following a partnership agreement. At the time of writing, the biopharmaceutical company’s shares are up 1.92% to $2.66. What did Paradigm announce? Par...

Source: Source: janews , Shutterstock   Healthcare takes over 1/10th per cent of the GDP of the most developed countries and the US contributes the most to this industry. As the coronavirus pandemic hit hard every industry, including hea...

The Paradigm Biopharmaceuticals Ltd [ASX:PAR] share price is up more than 4%, trading at $2.51. The PAR share price has largely traded sideways since October... The post Paradigm Biopharmaceuticals Shares Up on IND Application (ASX:PAR) app...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.45% to 6,820.8 points. Four ASX shares that are climbing more than most...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher on Friday. In early afternoon trade the biopharmaceutical company’s shares are up a sizeable 6% to $2.55. Why is the Paradigm share price charging higher today?...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce. The share price increase comes after Paradigm released its 1HY21 financial results. Here’s the rundow...

Paradigm is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury and inflammation.

The Phase 2 study will evaluate the treatment effect of Pentosan Polysulfate Sodium (PPS) (Zilosul®) compared with placebo on synovial fluid biomarkers in participants with knee osteoarthritis pain.